Trevi Therapeutics share price logo

Trevi Therapeutics

NASDAQ: TRVI

Mid Cap

$15.90

-0.01

(-0.06%)

as on

Trevi Therapeutics Stock Performance

as on September 12, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $15.89
    $16.57
    downward going graph

    0.06%

    Downside

    4.21%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $7.65
    $20.22
    downward going graph

    51.92%

    Downside

    27.17%

    Upside

    downward going graph

Trevi Therapeutics share price movements today

Previous Close
$15.91
Open
$16.20
Volume
1.3M
Market Cap
$2.4B
Day's Low - High
$15.89 - $16.57
52 Week Low - High
$7.65 - $20.22

Trevi Therapeutics Historical Returns

1 Month Return
-6.52 %
3 Month Return
+ 24.18 %
1 Year Return
+ 72.97 %
3 Year Return
+ 670.37 %
5 Year Return
+ 994.74 %

Trevi Therapeutics Stock Fundamentals & Key Indicators

Check Trevi Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.4B

EPS (TTM)

-0.479

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-59.4M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-19.66%

Trevi Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Trevi Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$2.4B994.74%NA0.00%NA
BUY$44.6B614.61%NA0.00%NA
BUY$138.4B181.2%30.5486.04%NA
BUY$56.0B-69.82%-16.99-12.57%NA
BUY$85.2B24.16%19.2884.86%45.660000000000004%

Stock Returns calculator for Trevi Therapeutics Stock including INR - Dollar returns

The Trevi Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Trevi Therapeutics investment value today

Current value as on today

₹1,79,213

Returns

₹79,213

(+79.21%)

Returns from Trevi Therapeutics Stock

₹65,281 (+65.28%)

Dollar Impact

₹13,932 (+13.93%)

Analyst Recommendation on Trevi Therapeutics Stock

Based on 10 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 10 analysts, 100% of analysts recommend a 'BUY' rating for Trevi Therapeutics. Average target price of $28.18

Trevi Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Trevi Therapeutics.

What analysts predicted

43.58%UPSIDE

Target Price

$28.18

Current Price

$15.9

Analyzed by

10 Analysts

Target

$28.18

Trevi Therapeutics target price $28.18, a slight upside of 43.58% compared to current price of $15.9. According to 10 analysts rating.

Indian Investors' Interest in Trevi Therapeutics Stock

Search interest for Trevi Therapeutics Stock has decreased by -70% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-70% versus previous 30 day period

Trevi Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
0
-
-
-
-
-
-
Gross Profit
0
0
0
0
0
0
-
0
0
-
Operating Income
-11
-13
-14
-12
-11
-13
-13
-10
-14
-20
EBITDA
-10
-12
-13
-11
-10
-12
-11
-8
-13
-17
Interest Expense
0
0
0
0
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-10
-12
-13
-11
-10
-12
-11
-8
-13
-17
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-10
-12
-13
-11
-10
-12
-11
-8
-13
-17
Net Profit Margin
0.00%
0.00%
0.00%
-7818.49%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Trevi Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
0
-
0
0
0
0
0
0
0
0
Operating Income
-8
-8
-18
-26
-32
-32
-29
-33
-51
-49
EBITDA
-8
-8
-18
-26
-32
-32
-29
-28
-47
-42
Interest Expense
-
3
0
0
0
1
0
0
0
-
Depreciation
-
0
0
0
0
0
0
0
0
0
Income Before Tax
-11
-12
-20
-26
-32
-33
-29
-29
-47
-42
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-11
-12
-20
-26
-32
-33
-29
-29
-47
-42
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Trevi Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-12
-13
-11
-10
-12
-11
-8
-13
-17
Operating Cash Flow
-8
-9
-9
-13
-10
-10
-7
-16
-17
Investing Cash Flow
2
7
-23
-9
-2
-50
-30
16
-112
Financing Cash Flow
5
4
51
8
110
1
0
0
164
Change in Cash
0
3
18
-14
97
-60
-37
0
34

Trevi Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-12
-20
-26
-32
-33
-29
-29
-47
-42
Operating Cash Flow
-7
-18
-23
-29
-28
-28
-31
-38
-42
Investing Cash Flow
0
0
0
0
-107
-107
59
-21
-94
Financing Cash Flow
21
0
73
16
20
111
-7
61
121
Change in Cash
13
-14
50
-12
-8
-24
19
1
-15

Mutual Funds that own Trevi Therapeutics Stock

Check out the Mutual Funds with significant holdings in Trevi Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.411941%
4861193
Fidelity Select Portfolios
2.308099%
3288485
Fidelity Securities Fund
2.063789%
2940402
MUTUAL FUND SERIES TRUST
1.85735%
2646276
Fidelity Concord Street Trust
1.246939%
1776587

Global Institutional Holdings in Trevi Therapeutics

Funds
Holdings
Vanguard
4.63%
iShares
3.9%
Michael Rockefeller
2.86%
Andreas Halvorsen
1.08%
SPDR
0.81%

Insights on Trevi Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, TRVI has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, TRVI stock has moved up by 92.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 512.4% return, outperforming this stock by 419.7%

About Trevi Therapeutics

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
OrganisationTrevi Therapeutics
Headquarters195 Church Street, New Haven, CT, United States, 06510
IndustryBiotechnology
CEOMs. Jennifer L. Good
E-voting on sharesClick here to vote

Key Management of Trevi Therapeutics

Name

Title

Ms. Jennifer L. Good

Co-Founder, CEO, President, & Director

Dr. James V. Cassella Ph.D.

Chief Development Officer

Mr. Farrell Simon Pharm.D.

Chief Commercial Officer

Dr. Thomas R. Sciascia M.D.

Co-Founder & Chief Scientific Officer

Mr. David C. Hastings CPA

Chief Financial Officer & Principal Financial Officer

Mr. Christopher Galletta

Controller & Chief Accounting Officer

Katie McManus

Communications Manager

FAQs

What is Trevi Therapeutics share price today?

Trevi Therapeutics share price today is $15.90 as on at the close of the market. Trevi Therapeutics share today touched a day high of $16.57 and a low of $15.89.

What is the 52 week high and 52 week low for Trevi Therapeutics share?

Trevi Therapeutics share touched a 52 week high of $20.22 on and a 52 week low of $7.65 on . Trevi Therapeutics stock price today i.e. is closed at $15.90,which is 21.36% down from its 52 week high and 107.98% up from its 52 week low.

What is Trevi Therapeutics's market capitalisation today?

Trevi Therapeutics market capitalisation is $0.00T as on .

How to invest in Trevi Therapeutics Stock (TRVI) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Trevi Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Trevi Therapeutics Shares that will get you 0.0943 shares as per Trevi Therapeutics share price of $15.90 per share as on September 12, 2026 at 8:45 am IST.

What is the minimum amount required to buy Trevi Therapeutics Stock (TRVI) from India?

Indian investors can start investing in Trevi Therapeutics (TRVI) shares with as little as ₹95.55 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹955.50 in Trevi Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Trevi Therapeutics share’s latest price of $15.90 as on September 12, 2026 at 8:45 am IST, you will get 0.6289 shares of Trevi Therapeutics. Learn more about fractional shares .

What are the returns that Trevi Therapeutics has given to Indian investors in the last 5 years?

Trevi Therapeutics stock has given 994.74% share price returns and 29.74% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?